2. Search Result
Search Result
Results for "

modest

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

11

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50094
    Pictilisib
    Maximum Cited Publications
    68 Publications Verification

    GDC-0941

    		 PI3K Autophagy Apoptosis Cancer
    Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
    Pictilisib
  • HY-10617A
    Rucaparib
    45+ Cited Publications

    AG014699; PF-01367338

    		 PARP Cancer
    Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .
    Rucaparib
  • HY-17034A
    Dexmedetomidine hydrochloride
    25+ Cited Publications

    (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride

    		 Adrenergic Receptor Infection Cancer
    Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine hydrochloride
  • HY-12719
    Dexmedetomidine
    25+ Cited Publications

    (+)-Medetomidine; (S)-Medetomidine

    		 Adrenergic Receptor Neurological Disease Cancer
    Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine
  • HY-10617
    Rucaparib phosphate
    45+ Cited Publications

    AG-014699 phosphate; PF-01367338 phosphate

    		 PARP Cancer
    Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .
    Rucaparib phosphate
  • HY-102003
    Rucaparib monocamsylate
    35+ Cited Publications

    AG014699 monocamsylate; PF-01367338 monocamsylate

    		 PARP Cancer
    Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .
    Rucaparib monocamsylate
  • HY-117626
    LP-935509
    1 Publications Verification

    		 AAK1 Cyclin G-associated Kinase (GAK) SARS-CoV Infection Neurological Disease Inflammation/Immunology
    LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research .
    LP-935509
  • HY-W090292
    Olivetolic acid

    		Drug Intermediate Neurological Disease
    Olivetolic acid is a biosynthetic precursor of cannabinol acid (CBGA). Olivetolic acid exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Olivetolic acid can be used for the study of convulsion .
    Olivetolic acid
  • HY-20180
    Pictilisib dimethanesulfonate
    Maximum Cited Publications
    68 Publications Verification

    GDC-0941 dimethanesulfonate ; GDC-0941 (2 MeSO3H salt)

    		 PI3K Autophagy Apoptosis Cancer
    Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
    Pictilisib dimethanesulfonate
  • HY-15641
    FG-2216
    5+ Cited Publications

    IOX3; YM311

    		 HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo .
    FG-2216
  • HY-13895
    WHI-P154
    1 Publications Verification

    		 EGFR JAK Apoptosis Cancer
    WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC50s of 4 nM and 1.8 μM, respectively.
    WHI-P154
  • HY-10473
    Eprotirome

    KB2115

    		 Thyroid Hormone Receptor Metabolic Disease Endocrinology
    Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .
    Eprotirome
  • HY-P1095
    Ivachtin

    Caspase-3 Inhibitor VII

    		 Caspase Cardiovascular Disease Neurological Disease
    Ivachtin (Caspase-3 Inhibitor VII; compound 7a) is a nonpeptide, noncompetitive and reversibl caspase-3 inhibitor with an IC50 of 23 nM. Ivachtin has modest selectivity for the remaining caspases .
    Ivachtin
  • HY-B1618S
    Corticosterone-d8
    1 Publications Verification

    		 Isotope-Labeled Compounds Glucocorticoid Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Corticosterone-d8 is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
    Corticosterone-d8
  • HY-B0102C
    (R)-Fluoxetine hydrochloride

    		Serotonin Transporter Neurological Disease
    (R)-Fluoxetine hydrochloride, an antidepressant, is serotonin reuptake inhibitor (SSRI). (R)-Fluoxetine hydrochloride has modest affinity at the 5-HT2A and 5-HT2C receptors .
    (R)-Fluoxetine hydrochloride
  • HY-132822
    Ivospemin

    SBP-101

    		 Drug Derivative Cancer
    Ivospemin (SBP-101) is an antineoplastic spermine analog. Ivospemin has shown efficacy in slowing pancreatic and ovarian tumor progression in vitro and in vivo. Ivospemin shows modest induction of polyamine catabolism, but stronger repression of ornithine decarboxylase activity. Ivospemin is promising for research of cancers .
    Ivospemin
  • HY-15046
    EB-47
    5 Publications Verification

    		 PARP Cardiovascular Disease Inflammation/Immunology
    EB-47, a potent and selective PARP-1/ARTD-1 inhibitor with an IC50 value of 45 nM, shows modest potency against ARTD5 with an IC50 value of 410 nM. EB-47 mimics the substrate NAD + and extends from the nicotinamide to the adenosine subsite .
    EB-47
  • HY-50094R
    Pictilisib (Standard)

    GDC-0941 (Standard)

    		 PI3K Autophagy Apoptosis Reference Standards Cancer
    Pictilisib (Standard) is the analytical standard of Pictilisib. This product is intended for research and analytical applications. Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
    Pictilisib (Standard)
  • HY-133146
    DJ001

    		Phosphatase Apoptosis Inflammation/Immunology
    DJ001 is a highly specific, selective and non-competitive protein tyrosine phosphatase-σ (PTPσ) inhibitor with an IC50 of 1.43 μM. DJ001 displays no inhibitory activity against other phosphatases, with only modest inhibitory activity against Protein Phosphatase 5. DJ001 promotes promote hematopoietic stem cell regeneration .
    DJ001
  • HY-100809
    Guvacine hydrochloride
    1 Publications Verification

    		 GABA Receptor Neurological Disease
    Guvacine hydrochloride is an alkaloid from the nut of Areca catechu, acts as an inhibitor of GABA transporter, and dispalys modest selectivity for cloned GABA transporters with IC50s of 14 μM (human GAT-1), 39 μM (rat GAT-1), 58 μM (rat GAT-2), 119 μM (human GAT-3), 378 μM (rat GAT-3), and 1870 μM (human BGT-3).
    Guvacine hydrochloride
  • HY-B1737
    Pirenperone

    R 47465

    		 5-HT Receptor Neurological Disease
    Pirenperone (R 47465) is a 5-HT2 serotonin receptor antagonist. Pirenperone exhibits modest anxiolytic activity .
    Pirenperone
  • HY-119529
    Jineol

    3,8-Quinolinediol

    		 Tyrosinase Bacterial Cancer
    Jineol is a cytotoxic alkaloid from the centipede Scolopendra subspinipes. Jineol exhibits modest cytotoxic activity in vitro against the growth of human tumor cell lines .
    Jineol
  • HY-108631
    EB-47 dihydrochloride
    5 Publications Verification

    		 PARP Inflammation/Immunology
    EB-47 dihydrochloride, a potent and selective PARP-1/ARTD-1 inhibitor with an IC50 value of 45 nM, shows modest potency against ARTD5 with an IC50 value of 410 nM. EB-47 mimics the substrate NAD +?and extends from the nicotinamide to the adenosine subsite .
    EB-47 dihydrochloride
  • HY-B1618S1
    Corticosterone-d4

    17-Deoxycortisol-d4; 11β,21-Dihydroxyprogesterone-d4; Kendall's compound B-d4

    		 Isotope-Labeled Compounds Glucocorticoid Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Corticosterone-d4 is the deuterium labeled Corticosterone. Corticosterone is an adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
    Corticosterone-d4
  • HY-17034AR
    Dexmedetomidine hydrochloride (Standard)

    (+)-Medetomidine hydrochloride (Standard); (S)-Medetomidine hydrochloride (Standard)

    		 Reference Standards Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine (hydrochloride) (Standard) is the analytical standard of Dexmedetomidine (hydrochloride). This product is intended for research and analytical applications. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine hydrochloride (Standard)
  • HY-12719R
    Dexmedetomidine (Standard)

    (+)-Medetomidine (Standard); (S)-Medetomidine (Standard)

    		 Reference Standards Adrenergic Receptor Neurological Disease Cancer
    Dexmedetomidine (Standard) is the analytical standard of Dexmedetomidine. This product is intended for research and analytical applications. Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine (Standard)
  • HY-W587780
    Sulfamethoxazole-NO

    SMX-NO

    		 Biochemical Assay Reagents Inflammation/Immunology
    Sulfamethoxazole-NO (SMX-NO) is the major immunogen in sulfonamide allergy, producing modest ascorbic acid depletion and hemoglobin adduct formation. Sulfamethoxazole-NO haptens tissue proteins and is immunogenic in rodents .
    Sulfamethoxazole-NO
  • HY-W013788
    2-Palmitoylglycerol

    2-Palm-Gl

    		 Cannabinoid Receptor Neurological Disease
    2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .
    2-Palmitoylglycerol
  • HY-145830
    AC1-IN-1

    		Adenylate Cyclase Neurological Disease
    AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC50 of 0.54 μM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain .
    AC1-IN-1
  • HY-111345
    Epaminurad

    UR-1102; URC-102

    		 OAT URAT1 Metabolic Disease Inflammation/Immunology
    Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research .
    Epaminurad
  • HY-N1965
    Gaultherin

    		NF-κB p38 MAPK COX Monoamine Oxidase MMP Interleukin Related TNF Receptor Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology
    Gaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC50 = 0.35 mg/mL), LOX (IC50 = 0.56 mg/mL) and HYAL (IC50 = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654) .
    Gaultherin
  • HY-18010
    PCI 29732
    3 Publications Verification

    		 Btk BCRP Inflammation/Immunology
    PCI 29732 is a potent, orally active, reversible BTK inhibitor with Ki app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .
    PCI 29732
  • HY-102003A
    Rucaparib camsylate

    AG014699 camsylate; PF-01367338 camsylate

    		 PARP Cancer
    Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research .
    Rucaparib camsylate
  • HY-150619
    KDM4-IN-4

    		Histone Demethylase Cancer
    KDM4-IN-4 (compound 47) is a potent histone lysine demethylase 4 (KDM4) inhibitor with a modest affinity binding to ~80 μM for KDM4A-Tudor domain. KDM4-IN-4 can inhibit H3K4Me3 binding to the Tudor domain in cells with an EC50 value of 105 μM. KDM4-IN-4 can be used for researching anticancer .
    KDM4-IN-4
  • HY-126291
    GNE-616

    		Sodium Channel Neurological Disease
    GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype selective Nav1.7 inhibitor (Ki of 0.79 nM and Kd of 0.38 nM for hNav1.7) for the treatment of chronic pain. GNE-616 shows >1000 nM Kd and >2500-fold selectivity over hNav1.1, hNav1.3, hNav1.4, and hNav1.5. Selectivity over hNav1.2 and hNav1.6 is more modest at 31- and 73-fold, respectively .
    GNE-616
  • HY-N3211
    N-cis-Feruloyl tyramine

    cis-N-(4-Hydroxyphenethyl) ferulamide; cis-N-Feruloyltyramine

    		 NO Synthase Inflammation/Immunology
    N-cis-Feruloyl tyramine (cis-N-(4-Hydroxyphenethyl) ferulamide) is a natural phenolic compound, exhibits modest inhibitory activity on LPS-activated NO production in RAW 264.7 cells .
    N-cis-Feruloyl tyramine
  • HY-135236
    OXFBD04

    		Epigenetic Reader Domain Cancer
    OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity .
    OXFBD04
  • HY-113876
    2-Methyl-3-phenylquinoxaline

    		PDGFR Cancer
    2-Methyl-3-phenylquinoxaline (compound 38) is a potent platelet-derived growth factor receptor tyrosine kinase (PDGF-RTK) inhibitor with modest inhibitory activity against PDGFR kinase in intact cells (IC50 greater than 100 μM) .
    2-Methyl-3-phenylquinoxaline
  • HY-132822A
    Ivospemin hydrochloride

    SBP-101 hydrochloride

    		 Drug Derivative Cancer
    Ivospemin (SBP-101) hydrochloride is an antineoplastic spermine analog. Ivospemin hydrochloride has shown efficacy in slowing pancreatic and ovarian tumor progression in vitro and in vivo. Ivospemin hydrochloride shows modest induction of polyamine catabolism, but stronger repression of ornithine decarboxylase activity. Ivospemin hydrochloride is promising for research of cancers .
    Ivospemin hydrochloride
  • HY-111345A
    Epaminurad hydrochloride

    UR-1102 hydrochloride; URC-102 hydrochloride

    		 OAT URAT1 Metabolic Disease Inflammation/Immunology
    Epaminurad (UR-1102) hydrochloride is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research .
    Epaminurad hydrochloride
  • HY-10617B
    Rucaparib hydrochloride

    AG014699 hydrochloride; PF-01367338 hydrochloride

    		 PARP Cancer
    Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .
    Rucaparib hydrochloride
  • HY-15641R
    FG-2216 (Standard)

    IOX3 (Standard); YM311 (Standard)

    		 HIF/HIF Prolyl-Hydroxylase Reference Standards Metabolic Disease
    FG-2216 (Standard) is the analytical standard of FG-2216. This product is intended for research and analytical applications. FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo .
    FG-2216 (Standard)
  • HY-10617C
    Rucaparib tartrate

    AG-014699 tartrate; PF-01367338 tartrate

    		 PARP Cancer
    Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research .
    Rucaparib tartrate
  • HY-17034AS
    Dexmedetomidine-13C,d3 hydrochloride

    (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride

    		 Isotope-Labeled Compounds Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine- 13C,d3 (hydrochloride) is the 13C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine-13C,d3 hydrochloride
  • HY-10617AR
    Rucaparib (Standard)

    AG014699 (Standard); PF-01367338 (Standard)

    		 Reference Standards PARP Cancer
    Rucaparib (Standard) is the analytical standard of Rucaparib. This product is intended for research and analytical applications. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .
    Rucaparib (Standard)
  • HY-175422
    K-833

    		GPR119 Metabolic Disease
    K-833 is a GPR119 agonist with EC50 values of 39.8 nM (human), 100nM (mouse), 75.4 nM (rat) and 12.6 nM (dog). K-833 demonstrates a modest increase in GLP-1 secretion and leads to a synergistic increase in GLP-1 levels when combined with AM-5262 (HY-16619) in acute gut peptide secretion assays in mice. K-833 can be used in studies on weight loss .
    K-833
  • HY-117734
    PYD-106

    		iGluR Neurological Disease
    PYD-106 is a stereoselective pyrrolidinone (PYD) positive allosteric modulator for GluN2C-containing NMDA receptors. PYD-106 increases opening frequency and open time of single channel currents activated by maximally effective concentrations of agonist but only has modest effects on glutamate and glycine EC50. PYD-106 selectively enhances the responses of diheteromeric GluN1/GluN2C receptors but not triheteromeric GluN1/GluN2A/GluN2C receptors .
    PYD-106
  • HY-N8386
    Berkeleylactone F

    		Antibiotic Infection Cancer
    Berkeleylactone F is an antibiotic macrolide compound. Berkeleylactone F showed modest inhibition of CCRF-CEM leukemia cells .
    Berkeleylactone F
  • HY-117220
    Aspochalasin M

    		Others Cancer
    Aspochalasin M is a colorless solid. Aspochalasin M shows modest activity against HL-60 cells with an IC50 of 20.0 μM. Aspochalasin M has the potential for the research of leukemic disease .
    Aspochalasin M
  • HY-163063
    Antimalarial agent 34

    		Parasite Infection
    Antimalarial agent 34 is a modest PfARK1/3 inhibitor and shows potent antiplasmodial activity (EC50 = 0.16 μM) .
    Antimalarial agent 34

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: